- Home
- AGIO vs DBRG Comparison
AGIO vs DBRG Comparison
Compare AGIO & DBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- DBRG
- Stock Information
- Founded
- AGIO 2007
- DBRG 1991
- Country
- AGIO United States
- DBRG United States
- Employees
- AGIO N/A
- DBRG N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- DBRG Real Estate Investment Trusts
- Sector
- AGIO Health Care
- DBRG Real Estate
- Exchange
- AGIO Nasdaq
- DBRG Nasdaq
- Market Cap
- AGIO 2.4B
- DBRG 2.3B
- IPO Year
- AGIO 2013
- DBRG 2009
- Fundamental
- Price
- AGIO $41.13
- DBRG $12.98
- Analyst Decision
- AGIO Strong Buy
- DBRG Strong Buy
- Analyst Count
- AGIO 4
- DBRG 7
- Target Price
- AGIO $59.33
- DBRG $16.00
- AVG Volume (30 Days)
- AGIO 514.0K
- DBRG 3.9M
- Earning Date
- AGIO 10-30-2025
- DBRG 10-30-2025
- Dividend Yield
- AGIO N/A
- DBRG 0.32%
- EPS Growth
- AGIO N/A
- DBRG N/A
- EPS
- AGIO 11.13
- DBRG N/A
- Revenue
- AGIO $40,875,000.00
- DBRG $173,540,000.00
- Revenue This Year
- AGIO $23.74
- DBRG N/A
- Revenue Next Year
- AGIO $159.90
- DBRG $77.07
- P/E Ratio
- AGIO $3.77
- DBRG N/A
- Revenue Growth
- AGIO 30.57
- DBRG N/A
- 52 Week Low
- AGIO $23.42
- DBRG $6.41
- 52 Week High
- AGIO $62.58
- DBRG $16.79
- Technical
- Relative Strength Index (RSI)
- AGIO 50.11
- DBRG 58.12
- Support Level
- AGIO $41.24
- DBRG $12.46
- Resistance Level
- AGIO $44.25
- DBRG $12.90
- Average True Range (ATR)
- AGIO 1.52
- DBRG 0.83
- MACD
- AGIO -0.16
- DBRG 0.02
- Stochastic Oscillator
- AGIO 31.28
- DBRG 63.96
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.